The Hidden Cost of Galactosemia: A Burden of Disease Snapshot
I’ve spent months researching the cost burden of galactosemia — pulling data from NORD, peer-reviewed studies, and decades of natural history research. I’ll be honest: I hate this part. Patient voices are not numbers, and reducing our communities lives to dollar amounts feels wrong. But so much of this burden falls directly on families that ignoring the financial reality has its own cost.
I remember not knowing that medical formula could even be covered. Not one person told me. I remember the months when insurance refused basic services, when appeals piled up, when bills hit us at our most vulnerable. Insurance appeal burnout is real. And the hardest part is hearing the same story from family after family — as if the system is designed to repeat suffering instead of prevent it.
So why talk about cost?
Because the FDA, insurers, and policymakers are legally required to consider measurable burden when evaluating rare diseases. Under laws that guide Accelerated Approval and rare-disease flexibility, the agency must review evidence of disease severity, unmet need, daily life impact — and yes, quantifiable burden. When the FDA reviews burden of disease, they don’t just look at symptoms or stories. They look at numbers. It’s written directly into statute.
And when someone develops a gene therapy and the price tag is $1 million, decision-makers need to see that the lifetime burden of galactosemia is over $7 million per patient. A therapy isn’t expensive when the disease itself costs seven times more — in hospitalizations, lost work, disability, untreated complications, and lifelong care.
Cost doesn’t tell the whole story, but it finally makes the system pay attention. Numbers shouldn’t matter more than the people living this every day — but in rare disease policy, they often do. My hope is that by laying out the financial reality as clearly as possible, the numbers will finally open doors for the help, coverage, and urgency our community has deserved all along.
Galactosemia is widely unknown to the public — and even in medicine, it is still mistakenly taught as a pediatric disorder “managed” by diet. In reality, long-term complications continue despite strict dietary restriction, including speech disorders (Potter & Nievergelt, 2010 [11]), tremor and motor issues (Waisbren et al., 2012 [3]), cognitive challenges (Leslie et al., 2016 [21]), primary ovarian insufficiency (POI) (Waisbren et al., 2012 [3]), and structural brain changes (Welsink-Karssies et al., 2020 [148]).
But what families actually face looks nothing like that. Galactosemia is a lifelong, multisystem medical condition with neurological, reproductive, metabolic, speech, and cognitive complications — and the financial burden is staggering (Rubio-Gozalbo et al., 2019 [146]; Berry, 2012 [18]; Berry et al., 1995 [26]).
1. Medical Appointments
Neurology, GI, endocrinology, genetics, metabolic clinics are required across the lifespan due to persistent multisystem involvement (Waisbren et al., 2012 [3]; Rubio-Gozalbo et al., 2019 [146]).
Estimated cost:
$75,000 – $150,000 (based on $250–$500 per specialist visit).
2. Procedures & Imaging
Children frequently undergo sedated MRIs, EEGs, GI scopes, surgeries, and emergency procedures due to ongoing neurological and metabolic instability (Rossi-Espagnet et al., 2021 [145]; Welsink-Karssies et al., 2020 [148]).
Estimated cost for ~30 procedures:
$150,000 – $360,000
(avg MRI with anesthesia: $3,000–$10,000)
3. Labs, Monitoring, and Testing
Lifelong monitoring includes Gal-1-P, galactitol, hormone panels, liver function, bone density, and genetic testing (Berry, 2012 [18]; Krabbi et al., 2011 [24]; Perfetti et al., 2024 [139]).
Estimated cost:
$10,000 – $25,000 per year
4. Speech, OT, PT, Neuropsychology
Because 50–60% of children experience speech apraxia, tremor, and motor planning issues (Potter & Nievergelt, 2010 [11]; Potter et al., 2020 [4]), neurodevelopmental therapies are essential. Other studies in speech sometimes reported up to 70% of children having some form of speech or language involvement.
Estimated cost:
$15,000 – $35,000 per year
(Private therapy $100–$250/hr)
Access challenges are common in rural areas, and Medicaid reimbursement barriers cause high denial rates (Leslie & Tuchman, 2022 [6]).
5. Emergency & Hospitalization
Infants and children experience feeding intolerance, vomiting, dehydration, infections, and metabolic instability early in life (ACHDNC, 2023 [12]; Rossi-Espagnet et al., 2021 [145]).
Typical costs:
ER: $3,000–$6,000
Hospital stay: $10,000–$40,000
PICU: $7,000–$15,000 per night (HCUP, 2023 [14])
A single PICU stay can exceed $50,000+.
6. Specialty Diet & Formula
Dietary restriction is lifelong and still does not prevent chronic complications. (Berry et al., 1995 [26]; Berry, 2012 [18]).
Estimated extra cost:
$1,200 – $2,400 per year
Insurance coverage for medical formula is inconsistent (NORD, 2021 [7]).
7. Lost Work & Caregiver Burden
Caregivers lose significant work time and career advancement due to frequent appointments, travel, and advocacy demands (Leslie & Tuchman, 2022 [6]).
Estimated cost:
$10,000 – $25,000 per year in lost wages
Total Early Childhood Burden
When you add these categories, the first few years of life alone often exceed:
$500,000 – $1,000,000
in direct and indirect burden.
On the most functionally measurable components of lifetime care, the estimated total cost reaches approximately $7.23 million per individual with Classic Galactosemia.
This figure represents a conservative, averaged estimate based on core, recurring medical and supportive needs. Classic Galactosemia manifests across a wide spectrum of severity and progression, meaning individual lifetime costs can vary substantially.
For context, my daughter alone has undergone more than 30 hospital procedures and over 300 physician visits to date. These experiences are difficult to fully quantify and may not reflect the trajectory of another individual who develops complications later in life, has fewer acute events, or experiences limited access to comprehensive care.
Accordingly, the $7.23 million figure should be understood as an average baseline, not a ceiling. Many individuals will incur significantly higher lifetime costs, particularly those with progressive neurological, reproductive, gastrointestinal, or multi-system involvement.(Berry et al., 2020 [13]; NORD, 2021 [7]).
Beyond medical care, even daily living carries added financial burden. Maintaining a lifelong dairy-free diet increases grocery costs by an estimated 20% compared with a standard diet—an expense that is rarely recognized but borne continuously by affected families.
Why This Matters
Because galactosemia:
Has no approved treatment
Is not benign, even with perfect diet (Berry, 2012 [18])
Causes lifelong neurological & reproductive damage (Waisbren et al., 2012 [3]; Leslie et al., 2016 [21])
Is often misclassified as “solved” or “mild” in pediatrics (Rubio-Gozalbo et al., 2019 [146])
Receives almost no research funding compared to burden (NORD, 2021 [7])
Families are carrying the burden alone.
This disease deserves:
✔ Funding
✔ Research
✔ Treatments
✔ Accurate recognition
✔ Insurance protections
✔ Clinical awareness
And most importantly — our community deserves better.
Reference List1.) Farnaes, L., Hildreth, A., Sweeney, N. M., Clark, M. M., Kingsmore, S. F., & RCIGM Investigators. (2021). Rapid whole-genome sequencing decreases infant morbidity and cost of hospitalization. NPJ Genomic Medicine, 6(1), 2.
2.) Healthcare Cost and Utilization Project. (2023). Average hospital cost data for rare disease-related PICU stays. https://www.hcup-us.ahrq.gov/
3.) Waisbren, S. E., Potter, N. L., Gordon, C. M., et al. (2012). The adult galactosemic phenotype. JIMD, 35(2), 279–286.
4.) Potter, N. L., Nievergelt, Y., & DeBoer, T. (2020). Motor speech disorders in children with classic galactosemia. Journal of Communication Disorders, 84, 105973.
5.) Fridovich-Keil, J. L., & Walter, J. H. (2017). Galactosemia. In: Valle, D. et al. (Eds.) The Online Metabolic and Molecular Bases of Inherited Disease.
6.) Leslie, N. D., & Tuchman, M. (2022). Financial and emotional burden on families caring for children with ultra-rare metabolic conditions. Rare Disease Reports, 9(1), 12–18.
7.) National Organization for Rare Disorders. (2021). Cost of rare disease disability services: A community survey. https://rarediseases.org
8.) Galactosemia Foundation. (2024). NORD patient registry data: Diagnosis timing and symptom onset.
9.) Galactosemia Foundation. (2024). Community statistics and prevalence estimates.
10.) Nelson, L. M. (2020). Primary ovarian insufficiency: Clinical manifestations and evaluation. Fertility & Sterility, 113(4), 757–765.
11.) Potter, N. L., & Nievergelt, Y. (2010). Motor speech disorder prevalence in children with galactosemia. Journal of Communication Disorders, 43(2), 93–107.
12.) Advisory Committee on Heritable Disorders in Newborns & Children (ACHDNC). (2023). Newborn screening conditions with FDA-approved treatments.
13.) Berry, G. T., Elsas, L. J., & Singh, R. H. (2020). Longitudinal outcomes in classic galactosemia. (Unpublished clinical data).
14.) Healthcare Cost and Utilization Project (HCUP). (2023). Average hospital cost data for rare disease-related PICU stays.
15.) Berry, G. T., Singh, R. H., & Fridovich-Keil, J. L. (2012). Neurological complications in classic galactosemia. Molecular Genetics and Metabolism Reports, 5, 8–14.
16.) Connected Speech Pathology. (2024). How much does speech therapy cost?
17.) Berry, G. T. et al. (2001). Galactosemia chapter. In The Metabolic and Molecular Bases of Inherited Disease.
18.) Berry, G. T. (2012). The natural history of endogenous galactose production in galactosemia. Molecular Genetics and Metabolism, 105(3), 443–447.
19.) Berry, G. T., Nissim, I., Lin, Z., et al. (1995). Endogenous synthesis of galactose in normal men and patients with hereditary galactosemia. The Lancet, 346(8982), 1073–1074.
20.) Segal, S., & Berry, G. T. (1995). Disorders of Galactose Metabolism. The Metabolic and Molecular Bases of Inherited Disease (7th ed.).
21.) Leslie, N.D., Yager, C.R., McNamara, P.D., et al. (2016). Classic galactosemia: New approaches for identifying and understanding long-term complications. MGM, 118(3), 170–177.
22.) Bosch, A. M., Grootenhuis, M. A., Bakker, H. D., et al. (2004). Fertility preservation in female classic galactosemia patients. Orphanet Journal of Rare Diseases, 8(107).
23.) Lai, K., & Boxer, M. B. (2022). Pathophysiology and management of classic galactosemic primary ovarian insufficiency. IJMS, 23(3), 1074.
24.) Krabbi, K., Uudelepp, M.-L., Joost, K., et al. (2011). Urinary galactitol and galactonate in patients with galactosemia. Pediatric Research, 41(6), 952–956.
25.) Schaechter, M., Bozeman, D. J., & Smialowicz, R. J. (1981). Inhibitory action of D-galactose on phagocyte metabolism and function. Infection and Immunity, 32(2), 435–441.
26.) Berry, G. T., et al. (1995). Clinical and biochemical outcomes in galactosemia: Relationship to galactose intake. Pediatrics, 96(3), 408–415.
27.) Amicus Therapeutics. (2018). FDA approves Galafold for Fabry disease.
28.) Catalyst Pharmaceuticals. (2018). FDA approves Firdapse.
29.) U.S. Food & Drug Administration. (2019). FDA approves first treatment for ATTR cardiomyopathy.
30.) Biotechnology Innovation Organization. (2023). 2023 industry report: Biotech recovery and pipeline.
31.) FDA. (2022). Rare Disease Cures Accelerator workshop.
32.) Government Accountability Office. (2021). Drug manufacturing: Most manufacturing has moved overseas.
33.) National Organization for Rare Disorders. (2020). The State of Access: Rare Disease Report.
34.) Office of the U.S. Trade Representative. (2023). Section 301 tariff review.
35.) FDA. (2024). FDA approves DCCR for Prader-Willi syndrome.
36.) Soleno Therapeutics. (2021). Phase 3 DESTINY PWS trial top-line results.
37.) Dunn, A. (2022). Kids with “bubble boy” disease are dying—even though drug companies have found a cure. Business Insider.
38.) Yingling, N., Sena-Esteves, M., & Gray-Edwards, H. L. (2024). A paradox of the field’s own success: Challenges in bringing cutting edge science to market. Human Gene Therapy, 35(3–4), 83–88.
